The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Zoldonrasib plus chemotherapy in first-line RAS G12D metastatic PDAC
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, explores preliminary safety and efficacy data from a Phase I/II study (NCT06445062) evaluating zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, combined with mFOLFIRINOX or gemcitabine/nab-paclitaxel as first-line treatment for RAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC). Both combinations showed manageable toxicity consistent with known chemotherapy-related adverse events, with encouraging early response rates. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
